Researchers Seeking Alzheimer Patients for Phase Two Clinical Trial of Gene Therapy

Sept. 23, 2009 - Researchers in the Memory Disorders Program at Georgetown University Medical Center are now recruiting volunteers – ages 55 to 80 - for a national gene therapy trial – the first study of its kind for the treatment of patients with dementia due to Alzheimer's disease.

	Related Stories
	Senior Citizens Having Trouble Counting Coins May Indicate Early Sign of Alzheimer’s Disease Researchers find managing financial matters a good test for mild cognitive impairment Sept. 22, 2009 World Alzheimer’s Day Greeted with Bad News: 35 Million with Dementia in 2010, 65 Million by 2030 Dementia projected to double every 20 years by 2009 World Alzheimer’s Report Sept. 21, 2009 Caregivers & Elder Care News Challenges of Caregiving for Dementia Patients Explored in New World Alzheimer Report In Europe, 85% of couples (one with Alzheimer’s or other dementia, the other being their caregiver) lived on their own Sept. 21, 2009 Difficulties with Routine Activities Associated with Faster Progression to Dementia No demographic, cognitive or neuroimaging variables predicted this progression Sept. 14, 2009 Read the latest news on Alzheimer's, Dementia & Mental Health

The phase II study examines the safety and possible benefits of CERE-110. CERE-110 contains a gene and is injected during surgery into a part of the brain affected by Alzheimer's disease.

The gene will instruct brain cells to produce more of a protein, called Nerve Growth Factor or NGF, which helps nerve cells survive and function properly. The transfer of this gene into the brain is a medical technique called gene therapy.

"Our goal is to stop the progression of Alzheimer's disease," explains R. Scott Turner, MD, PhD, director of Georgetown's Memory Disorders Program. "This is our first study of a gene therapy injected into brain, and thus the trial requires close collaboration with our neurosurgery colleagues at GUMC, in particular Dr. Chris Kalhorn."

Turner says Kalhorn, an associate professor of the department of neurosurgery at Georgetown University Hospital, routinely performs neurosurgical procedures similar to the one being utilized in this study.

About 50 people with Alzheimer's disease will participate in this study at fewer than 10 hospitals nationwide.

Only persons with a mild form of Alzheimer's Disease, who are evaluated and deemed competent to consent for themselves, will be permitted to participate in the study.

The study requires each patient select a study partner for the length of the study.

All patients in the study will undergo surgery to drill two small holes in the skull. Only those patients randomly assigned to receive CERE-110 will have the gene therapy injected into the brain. Those subjects randomized to the placebo group will not have the gene therapy injected.

This study is a phase II, double-blind, placebo-controlled study.

Phase II means the investigational agent has been studied in a small number of patients and this study is being conducted to determine its safety and possible benefits.

Double-blind means that the patients, clinical coordinators and treating physicians will not know if the patient received the investigational agent until the end of the study. Only the neurosurgeon and operating team delivering the gene therapy will know if the patient received the active agent.

Placebo-controlled means that patients will be selected randomly to either receive the active agent or not, but all patients will undergo surgery. This study has been approved by the FDA and the Institutional Review Board at GUMC.

This study is sponsored by the Alzheimer's Disease Cooperative Study (ADCS) through a grant from the National Institute on Aging (a part of the NIH) in association with Ceregene, Inc, which will provide the active agent used in this study. GUMC will be reimbursed for the costs of performing the study by the ADCS. Turner, the study's lead investigator at Georgetown, has no financial interests to disclose.

The Memory Disorders Program is conducting several clinical studies for patients in the early stages of dementia due to Alzheimer's disease. Depending on the person's medical status, he or she may qualify and wish to participate in other studies.

To learn more about this study, call 202-784-6671 or Click Here.

To learn more about other studies, contact Georgetown's Memory Disorders Program at 202-784-6671 or visit the website at memory.georgetown.edu.

About Georgetown University Medical Center

Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through Georgetown's affiliation with MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person."

The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO), home to 60 percent of the university's sponsored research funding.